Conference Proceedings
Carfilzomib Thalidomide and Dexamethasone Is Safe and Effective in the Treatment of Relapsed/Refractory Multiple Myeloma: Preliminary Outcome from the Open Label Phase II ALLGMM018/AMN003 Study
Hang Quach, Simon J Harrison, Slavisa Ninkovic, Jane Estell, Noemi Horvath, Nick Murphy, Richard Eek, Bradley Augustson, Philip Campbell, Rajeev Rajagopal, Akash Kalro, Robyn Hemme, Belinda Butcher, Tracey Gerber, Peter Mollee, Brian GM Durie, Wee-Joo Chng
BLOOD | AMER SOC HEMATOLOGY | Published : 2018
Abstract
Abstract Background: Carfilzomib lenalidomide and dexamethasone (KRd) is FDA-approved for the treatment relapsed/refractory multiple myeloma (RRMM) based on data from the ASPIRE study (Stewart K et al. NEJM 2015). Thalidomide, a first generation immunomodulatory drug (IMiD) is less costly than lenalidomide and is synergistic in combination with proteasome inhibitors in the treatment of MM. ALLG MM018/ AMN003 is an open label phase II study of carfilzomib thalidomide and dexamethasone (KTd) for patients with RRMM. The primary end point is progression free survival (PFS). Secondary endpoints include overall response rate (ORR), duration of response (DOR), safety a..
View full abstract